Zachary Grunwald1, Lauren A Beslow2, Sebastian Urday2, Anastasia Vashkevich3, Alison Ayres3, Steven M Greenberg3, Joshua N Goldstein3, Audrey Leasure2, Fu-Dong Shi4, Kristopher T Kahle5, Thomas W K Battey3, J Marc Simard6, Jonathan Rosand3, W Taylor Kimberly3, Kevin N Sheth2. 1. Department of Neurology, Yale School of Medicine, 15 York Street, Bldg. LLCI, 10th Floor, 1003C, New Haven, CT, 06510, USA. zachary.grunwald@yale.edu. 2. Department of Neurology, Yale School of Medicine, 15 York Street, Bldg. LLCI, 10th Floor, 1003C, New Haven, CT, 06510, USA. 3. Center for Human Genetic Research and Division of Neurocritical Care and Emergency Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. 5. Departments of Neurosurgery, Pediatrics, and Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT, USA. 6. Departments of Neurosurgery, Pathology and Physiology, University of Maryland School of Medicine, Baltimore, MA, USA.
Abstract
BACKGROUND: Perihematomal edema (PHE) expansion rate may predict functional outcome following spontaneous intracerebral hemorrhage (ICH). We hypothesized that the effect of PHE expansion rate on outcome is greater for deep versus lobar ICH. METHODS: Subjects (n = 115) were retrospectively identified from a prospective ICH cohort enrolled from 2000 to 2013. Inclusion criteria were age ≥ 18 years, spontaneous supratentorial ICH, and known onset time. Exclusion criteria were primary intraventricular hemorrhage (IVH), trauma, subsequent surgery, or warfarin-related ICH. ICH and PHE volumes were measured from CT scans and used to calculate expansion rates. Logistic regression assessed the association between PHE expansion rates and 90-day mortality or poor functional outcome (modified Rankin Scale > 2). Odds ratios are per 0.04 mL/h. RESULTS: PHE expansion rate from baseline to 24 h (PHE24) was associated with mortality for deep (p = 0.03, OR 1.13[1.02-1.26]) and lobar ICH (p = 0.02, OR 1.03[1.00-1.06]) in unadjusted regression and in models adjusted for age (deep p = 0.02, OR 1.15[1.02-1.28]; lobar p = 0.03, OR 1.03[1.00-1.06]), Glasgow Coma Scale (deep p = 0.03, OR 1.13[1.01-1.27]; lobar p = 0.02, OR 1.03[1.01-1.06]), or time to baseline CT (deep p = 0.046, OR 1.12[1.00-1.25]; lobar p = 0.047, OR 1.03[1.00-1.06]). PHE expansion rate from baseline to 72 h (PHE72) was associated with mRS > 2 for deep ICH in models that were unadjusted (p = 0.02, OR 4.04[1.25-13.04]) or adjusted for ICH volume (p = 0.02, OR 4.3[1.25-14.98]), age (p = 0.03, OR 5.4[1.21-24.11]), GCS (p = 0.02, OR 4.19[1.2-14.55]), or time to first CT (p = 0.03, OR 4.02[1.19-13.56]). CONCLUSIONS: PHE72 was associated with poor functional outcomes after deep ICH, whereas PHE24 was associated with mortality for deep and lobar ICH.
BACKGROUND:Perihematomal edema (PHE) expansion rate may predict functional outcome following spontaneous intracerebral hemorrhage (ICH). We hypothesized that the effect of PHE expansion rate on outcome is greater for deep versus lobar ICH. METHODS: Subjects (n = 115) were retrospectively identified from a prospective ICH cohort enrolled from 2000 to 2013. Inclusion criteria were age ≥ 18 years, spontaneous supratentorial ICH, and known onset time. Exclusion criteria were primary intraventricular hemorrhage (IVH), trauma, subsequent surgery, or warfarin-related ICH. ICH and PHE volumes were measured from CT scans and used to calculate expansion rates. Logistic regression assessed the association between PHE expansion rates and 90-day mortality or poor functional outcome (modified Rankin Scale > 2). Odds ratios are per 0.04 mL/h. RESULTS:PHE expansion rate from baseline to 24 h (PHE24) was associated with mortality for deep (p = 0.03, OR 1.13[1.02-1.26]) and lobar ICH (p = 0.02, OR 1.03[1.00-1.06]) in unadjusted regression and in models adjusted for age (deep p = 0.02, OR 1.15[1.02-1.28]; lobar p = 0.03, OR 1.03[1.00-1.06]), Glasgow Coma Scale (deep p = 0.03, OR 1.13[1.01-1.27]; lobar p = 0.02, OR 1.03[1.01-1.06]), or time to baseline CT (deep p = 0.046, OR 1.12[1.00-1.25]; lobar p = 0.047, OR 1.03[1.00-1.06]). PHE expansion rate from baseline to 72 h (PHE72) was associated with mRS > 2 for deep ICH in models that were unadjusted (p = 0.02, OR 4.04[1.25-13.04]) or adjusted for ICH volume (p = 0.02, OR 4.3[1.25-14.98]), age (p = 0.03, OR 5.4[1.21-24.11]), GCS (p = 0.02, OR 4.19[1.2-14.55]), or time to first CT (p = 0.03, OR 4.02[1.19-13.56]). CONCLUSIONS:PHE72 was associated with poor functional outcomes after deep ICH, whereas PHE24 was associated with mortality for deep and lobar ICH.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Sebastian Urday; Lauren A Beslow; David W Goldstein; Anastasia Vashkevich; Alison M Ayres; Thomas W K Battey; Magdy H Selim; W Taylor Kimberly; Jonathan Rosand; Kevin N Sheth Journal: Stroke Date: 2015-02-26 Impact factor: 7.914
Authors: Anirudh Sreekrishnan; Jennifer L Dearborn; David M Greer; Fu-Dong Shi; David Y Hwang; Audrey C Leasure; Sonya E Zhou; Emily J Gilmore; Charles C Matouk; Nils H Petersen; Lauren H Sansing; Kevin N Sheth Journal: Neurocrit Care Date: 2016-12 Impact factor: 3.210
Authors: H Arima; J G Wang; Y Huang; E Heeley; C Skulina; M W Parsons; B Peng; Q Li; S Su; Q L Tao; Y C Li; J D Jiang; L W Tai; J L Zhang; E Xu; Y Cheng; L B Morgenstern; J Chalmers; C S Anderson Journal: Neurology Date: 2009-12-08 Impact factor: 9.910
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Adrian R Parry-Jones; Xia Wang; Shoichiro Sato; W Andrew Mould; Andy Vail; Craig S Anderson; Daniel F Hanley Journal: Stroke Date: 2015-05-05 Impact factor: 7.914
Authors: Jesse J Corry; Ganesh Asaithambi; Arif M Shaik; Jeffrey P Lassig; Emily H Marino; Bridget M Ho; Amy L Castle; Nilanjana Banerji; Megan E Tipps Journal: Clin Drug Investig Date: 2020-05 Impact factor: 2.859
Authors: Audrey C Leasure; Adnan I Qureshi; Santosh B Murthy; Hooman Kamel; Joshua N Goldstein; Kyle B Walsh; Daniel Woo; Fu-Dong Shi; Hagen B Huttner; Wendy C Ziai; Daniel F Hanley; Charles C Matouk; Lauren H Sansing; Guido J Falcone; Kevin N Sheth Journal: Stroke Date: 2019-07-05 Impact factor: 7.914
Authors: Alireza Shirazian; Andres F Peralta-Cuervo; Maria P Aguilera-Pena; Louis Cannizzaro; Vi Tran; Doan Nguyen; Ifeanyi Iwuchukwu Journal: Neurocrit Care Date: 2021-01-05 Impact factor: 3.210
Authors: Audrey C Leasure; Lindsey R Kuohn; Kevin N Vanent; Matthew B Bevers; W Taylor Kimberly; Thorsten Steiner; Stephan A Mayer; Charles C Matouk; Lauren H Sansing; Guido J Falcone; Kevin N Sheth Journal: Stroke Date: 2021-03-08 Impact factor: 7.914
Authors: Stefan P Haider; Adnan I Qureshi; Abhi Jain; Hishan Tharmaseelan; Elisa R Berson; Tal Zeevi; Shahram Majidi; Christopher G Filippi; Simon Iseke; Moritz Gross; Julian N Acosta; Ajay Malhotra; Jennifer A Kim; Lauren H Sansing; Guido J Falcone; Kevin N Sheth; Seyedmehdi Payabvash Journal: Eur J Neurol Date: 2021-07-18 Impact factor: 6.288